Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation
A Randomized, Double-blind, Vehicle Controlled Phase 1 Dermal Safety Study to Evaluate the Sensitizing Potential of Topically Applied Azelaic Acid Pre-foam Formulation in Healthy Subjects Using a Human Repeated Insult Patch Test Design
2 other identifiers
interventional
240
1 country
1
Brief Summary
The purpose of this study is to determine the dermal sensitization potential of azelaic acid pre-foam formulation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1 healthy
Started Sep 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2011
CompletedFirst Submitted
Initial submission to the registry
September 6, 2011
CompletedFirst Posted
Study publicly available on registry
September 8, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2011
CompletedApril 1, 2020
February 1, 2014
3 months
September 6, 2011
March 30, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
skin sensitization reaction
skin reactions will be assessed, using a standardized scoring scale
day 3 to 6 of challenge phase week (week 6 or later, at least 2 weeks after the 3 week induction phase)
Study Arms (3)
Verum
EXPERIMENTALTopical application of verum (azelaic acid pre foam formulation) on the skin
Vehicle
PLACEBO COMPARATORTopical application of vehicle formulation (same as verum but without active drug substance) on the skin
Negative control
PLACEBO COMPARATORTopical application of distilled water (negative control) on the skin
Interventions
Eligibility Criteria
You may qualify if:
- healthy volunteers
- male or female subjects
- aged 18 - 65 years
- ability to understand and fulfill the study requirements
You may not qualify if:
- affected skin in designated test area
- pregnancy or lactation
- not willing to comply with study requirements
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- LEO Pharmalead
- Bayercollaborator
Study Sites (1)
Robert I. Cooper, MD
Fargo, North Dakota, 58104, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bayer Study Director
Bayer
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 6, 2011
First Posted
September 8, 2011
Study Start
September 1, 2011
Primary Completion
December 1, 2011
Study Completion
December 1, 2011
Last Updated
April 1, 2020
Record last verified: 2014-02